$42.73
3.96% yesterday
Nasdaq, Dec 29, 10:02 pm CET
ISIN
US6402681083
Symbol
NKTR

Nektar Therapeutics Stock price

$42.73
-18.38 30.08% 1M
+16.89 65.36% 6M
+28.78 206.31% YTD
+28.57 201.77% 1Y
+9.73 29.48% 3Y
-231.02 84.39% 5Y
-218.42 83.64% 10Y
-200.42 82.43% 20Y
Nasdaq, Closing price Mon, Dec 29 2025
-1.76 3.96%
ISIN
US6402681083
Symbol
NKTR
Industry

Key metrics

Basic
Market capitalization
$869.2m
Enterprise Value
$599.0m
Net debt
positive
Cash
$270.2m
Shares outstanding
19.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.9 | 19.6
EV/Sales
9.6 | 13.5
EV/FCF
negative
P/B
10.2
Financial Health
Equity Ratio
20.0%
Return on Equity
-195.9%
ROCE
-58.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$62.6m | $44.4m
EBITDA
$-135.2m | $-141.5m
EBIT
$-136.4m | $-152.7m
Net Income
$-120.7m | $-208.2m
Free Cash Flow
$-190.4m
Growth (TTM | estimate)
Revenue
-32.8% | -54.9%
EBITDA
-3.8% | -12.7%
EBIT
-0.3% | -17.6%
Net Income
28.3% | -75.0%
Free Cash Flow
-7.1%
Margin (TTM | estimate)
Gross
87.3%
EBITDA
-216.0% | -318.9%
EBIT
-217.8%
Net
-192.9% | -469.3%
Free Cash Flow
-304.1%
More
EPS
$-6.4
FCF per Share
$-9.7
Short interest
9.7%
Employees
61
Rev per Employee
$1.6m
Show more

Is Nektar Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Nektar Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Nektar Therapeutics forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Nektar Therapeutics forecast:

Buy
86%
Hold
14%

Financial data from Nektar Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
63 63
33% 33%
100%
- Direct Costs 7.98 7.98
73% 73%
13%
55 55
14% 14%
87%
- Selling and Administrative Expenses 75 75
3% 3%
119%
- Research and Development Expense 116 116
5% 5%
186%
-135 -135
4% 4%
-216%
- Depreciation and Amortization 1.17 1.17
79% 79%
2%
EBIT (Operating Income) EBIT -136 -136
0% 0%
-218%
Net Profit -121 -121
28% 28%
-193%

In millions USD.

Don't miss a Thing! We will send you all news about Nektar Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nektar Therapeutics Stock News

Negative
Seeking Alpha
12 days ago
Nektar Therapeutics's results from REZOLVE-AA, a trial of rezpegaldesleukin in alopecia areata, have failed to stimulate a rally in the stock. Even with concerns about statistical significance in the trial results, the drug does look to have activity in alopecia areata. Further data is coming from the atopic dermatitis study, REZOLVE-AD in Q1 '26, and from REZOLVE-AA in early Q2'26, meaning the...
Neutral
Seeking Alpha
14 days ago
Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript
Neutral
PRNewsWire
14 days ago
SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a...
More Nektar Therapeutics News

Company Profile

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The firm focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Head office United States
CEO Howard Robin
Employees 61
Founded 1990
Website www.nektar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today